Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19712361 | 0.82 | CYP2D6 (0.36) | GRM2ATMCYP2D6KCNH2HRH3 | |
| SCHEMBL6523733 | 0.81 | SPR (0.32) | — | |
| SCHEMBL19815798 | 0.80 | GABRR1 (0.36) | MMP2ANPEP | |
| SCHEMBL16338418 | 0.79 | ATM (0.35) | ATMCYP2D6KCNH2HRH3 | |
| SCHEMBL16654344 | 0.75 | EPHX2 (0.33) | — | |
| SCHEMBL1907444 | 0.75 | — | — | |
| SCHEMBL6522699 | 0.75 | PLA2G1B (0.38) | MMP2ANPEP | |
| SCHEMBL20745368 | 0.75 | PLA2G1B (0.38) | MMP2ANPEP | |
| SCHEMBL20497839 | 0.75 | PLA2G1B (0.38) | MMP2ANPEP | |
| SCHEMBL27171915 | 0.75 | PLA2G1B (0.38) | MMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062491-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2023-03-02 | — | — | US | disclosed |
| US-10138256-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-11-27 | — | — | US | disclosed |
| US-9561228-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9504686-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-24 | — | — | US | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-8815863-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2014-08-26 | — | — | US | disclosed |
| US-8530468-B2 | Bicyclylaryl-aryl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-09-10 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120232082-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2012-09-13 | — | — | US | disclosed |
| US-20110301146-A1 | GLYCOGEN SYNTHASE KINASE-3 BETA INHIBITORS CONTAINING 7-HYDROXY-BENZOIMIDAZOLE-4-YL-METHANONE DERIVATIVES | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20100331328-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-30 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232082-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | CHEK2, CHEK1, BUB1B | GRM2 2903/4885MMP2 4687/4885ANPEP 3822/4885 |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | GRM2 761/4885MMP2 2492/4885ANPEP 3551/4885 |
| US-20110301146-A1 | GLYCOGEN SYNTHASE KINASE-3 BETA INHIBITORS CONTAINING 7-HYDROXY-BENZOIMIDAZOLE-4-YL-METHANONE DERIVATIVES | GSK3B, GSK3A, GYS2 | GRM2 1641/4885MMP2 2529/4885ANPEP 4433/4885 |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | GRM2 3132/4885MMP2 652/4885ANPEP 1030/4885 |
| US-20230062491-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | GRM2 4637/4885MMP2 1872/4885ANPEP 4585/4885 |
| US-10138256-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | GRM2 761/4885MMP2 2492/4885ANPEP 3551/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | GRM2 1479/4885MMP2 3154/4885ANPEP 3057/4885 |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | GRM2 2628/4885MMP2 1103/4885ANPEP 1402/4885 |
| US-20100331328-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CHEK1, CHEK2, BUB1B | GRM2 3008/4885MMP2 4442/4885ANPEP 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.